Computational Molecular Biology 2016, Vol.6, No.1, 1-20
16
organization , expression profiling and evolutionary aspects , Genomics, 85: 153–164.
Hoelder S., Clarke P., and Workman P., 2012, Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Molecular Oncology, 6(2):
1–22.
Hughes J., Rees S., Kalindjian S., and Philpott K., 2011, Principles of early drug discovery. British Journal of Pharmacology, 162(6): 1239–1249.
Hussain A.R., Ahmed S.O., Ahmed M., Khan O.S., Abdulmohsen, S. Al, Platanias, L. C., and Uddin, S., 2012, Cross-Talk between NFkB and the PI3-Kinase /
AKT Pathway Can Be Targeted in Primary Effusion Lymphoma ( PEL ) Cell Lines for Efficient Apoptosis, PLoS One, 7(6): 1–12.
Ingham R.J., Colwill K., Howard C., Dettwiler S., Lim C.S.H., Yu J., and Pawson T.,2005, WW Domains Provide a Platform for the Assembly of Multiprotein
Networks. Molecular and Cellular Biology, 25(16): 7092–7106.
Irwin J.J., Sterling T., Mysinger M.M., Bolstad E.S., and Coleman R.G., 2012, ZINC: A Free Tool to Discover Chemistry for Biology. Journal of Chemical
Information and Modeling, 52(7): 1757–1768.
Jardim D.L., Wheler J.J., Hess K., Tsimberidou A.M., Zinner R., Janku F., and Hong D.S., 2014, FBXW7 Mutations in Patients with Advanced Cancers:
Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE, 9(2).
Jia L., and Sun Y., 2012, SCF E3 Ubiquitin Ligases as Anticancer Targets. Curr Cancer Drug Targets, 11(3): 347–356.
Jones R.J., Bjorklund C.C., Baladandayuthapani V., Kuhn D.J., and Orlowski R.Z., 2012, Drug resistance to inhibitors of the human double minute-2 E3 ligase
is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Molecular Cancer Therapeutics, 11(10): 2243–53.
Karlsen A., Retterstøl L., Laake P., Paur I., Kjølsrud-bøhn S., and Sandvik L., 2007, Anthocyanins Inhibit Nuclear Factor- k B Activation in Monocytes and
Reduce Plasma Concentrations of Pro-Inflammatory Mediators in Healthy Adults 1 (3): 1951–1954.
Kearns J.D., Basak S., Werner S.L., Huang C.S., and Hoffmann A., 2006, IkappaBepsilon provides negative feedback to control NF-kappaB oscillations,
signaling dynamics, and inflammatory gene expression. The Journal of Cell Biology, 173(5): 659–64.
Kerrigan J.E., 2013, Molecular Dynamics Simulations in Drug Design. Methods Mol Biol., 993: 95–113.
Kitagaki J., Agama K.K., Pommier Y., Yang Y., and Weissman A.M., 2008, Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2
(8):2445–2455.
Koblish H.K., 2006, Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to
doxorubicin in vivo. Molecular Cancer Therapeutics, 5(1): 160–169.
Koti M., Siu A., Clément I., Bidarimath M., Turashvili G., Edwards A., and Squire J.A., 2015, A distinct pre-existing inflammatory tumour microenvironment is
associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. British Journal of Cancer, 112(7): 1215–1222.
Lain S., Hollick J.J., Campbell J., Staples O.D., Higgins M., Aoubala M., and Westwood N.J., 2008, Discovery, in vivo activity, and mechanism of action of a
small-molecule p53 activator. Cancer Cell, 13(5): 454–63.
Lamothe B., Campos A.D., Webster W.K., Gopinathan A., Hur L., and Darnay B.G., 2008, The RING Domain and First Zinc Finger of TRAF6 Coordinate
Signaling by Interleukin-1 , Lipopolysaccharide , and RANKL. J Biol Chem
.,
283(36): 24871–24880.
Landré V., Rotblat B., Melino S., and Bernassola F., 2014, Screening for E3-Ubiquitin ligase inhibitors : challenges and opportunities, Oncotarget,
5(18):7988-8013.
Landskron G., De la Fuente M., Thuwajit P., Thuwajit C., and Hermoso M. A., 2014, Chronic Inflammation and Cytokines in the Tumor Microenvironment.
Journal of Immunology Research, 2014:149185.
Lau L.M.S., Nugent J.K., Zhao X., and Irwin M.S., 2008, HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene, 27(7):
997–1003.
Lawrence T., 2009, The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harbor Perspectives in Biology, 1(6): 1-10.
Leeson P., 2012, Drug discovery: Chemical beauty contest. Nature, 481(7382): 455–456.
